Please Wait
Applying Filters...
menu
    • menu
    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Menu

    Bupropion Hydrochloride

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    $ API Ref.Price (USD/KG) : 63Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Teva agrees with Axsome to keep generic off market until 2038
    Teva agrees with Axsome to keep generic off market until 2038

    11 Feb 2025

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/axsome-shares-jump-21-settlement-teva-will-keep-auvelity-generic-market-until-2038

    FIERCE PHARMA
    11 Feb 2025
    Share Share
    Axsome Advances Alzheimer's Drug Despite Mixed Trial Data
    Axsome Advances Alzheimer's Drug Despite Mixed Trial Data

    31 Dec 2024

    // BIOSPACE

    https://www.biospace.com/press-releases/axsome-therapeutics-announces-successful-completion-and-results-of-phase-3-clinical-program-of-axs-05-in-alzheimers-disease-agitation

    BIOSPACE
    31 Dec 2024
    Share Share
    Enforcement Report - Week of December 13, 2023
    Enforcement Report - Week of December 13, 2023

    13 Dec 2023

    // FDA

    https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-december-13-2023-38736.pdf

    FDA
    13 Dec 2023
    Share Share
    Enforcement Report - Week of October 25, 2023
    Enforcement Report - Week of October 25, 2023

    25 Oct 2023

    // FDA

    https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-october-25-2023-66768.pdf

    FDA
    25 Oct 2023
    Share Share
    FDA Confirms Paragraph IV Patent Litigation for Dextromethorphan Hydrobromide and Bupropion Hydrochloride Extended-release Tablet
    FDA Confirms Paragraph IV Patent Litigation for Dextromethorphan Hydrobromide and Bupropion Hydrochloride Extended-release Tablet

    23 Feb 2023

    // FDA

    https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-litigation-for-dextromethorphan-hydrobromide-and-bupropion-hydrochloride-extended-release-tablet-83509.pdf

    FDA
    23 Feb 2023
    Share Share
    Enforcement Report - Week of February 22, 2023
    Enforcement Report - Week of February 22, 2023

    22 Feb 2023

    // FDA

    https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-february-22-2023-51785.pdf

    FDA
    22 Feb 2023
    Share Share